Modulation of Burn Hypermetabolism in Preclinical Models

Area of Science:

• Burn research
• Metabolic disorders
• Trauma medicine

Background:

• Severe burns induce a hypermetabolic state, increasing insulin resistance, muscle breakdown, and impairing healing.
• Despite interventions, burn hypermetabolism significantly contributes to patient morbidity and mortality.
• Animal models are essential for studying burn pathophysiology and testing new treatments due to in vitro limitations.

Purpose of the Study:

• To review novel therapies for modulating burn hypermetabolism.
• To assess the applicability and translation potential of these therapies.
• To guide researchers in selecting appropriate animal models for burn research.

Main Methods:

• Review of recent animal studies on burn hypermetabolism treatments.
• Analysis of therapies including growth hormone, erythropoietin, acipimox, apelin, anti-IL-6 antibody, and ghrelin.
• Examination of revisited clinical drugs like insulin and metformin for their mechanisms.

Main Results:

• Promising results from novel therapies suggest potential for human translation.
• Revisiting existing drugs like insulin and metformin offers new insights into burn hypermetabolism mechanisms.
• Animal studies provide a platform for evaluating treatment efficacy and safety.

Conclusions:

• Novel therapeutic strategies show promise in managing burn hypermetabolism.
• Understanding and utilizing appropriate animal models is key for advancing burn care.
• Continued research is vital for improving outcomes in severe burn patients.